CLOSE

The pressure to create a coronavirus vaccine is growing every day, but it takes time for a safe vaccine to hit the market.

USA today

The United States announced on Friday that it would pay French pharmaceutical company Sanofi and Britain’s GlaxoSmithKline up to $ 2.1 billion for testing and making 100 million doses of the experimental coronavirus vaccine.

More than half of the funds will support further development and early-stage clinical trials to ensure its safety and effectiveness. The rest will pay for the first 100 million doses, with the possibility of 500 million more.

Most of the $ 2.1 billion will go to Sanofi, who has become a candidate for the vaccine. GlaxoSmithKline has made a booster that improves how the body responds to it.

The deal is part of the White House operation Warp Speed, which aims to get a vaccine to stop SARS-CoV-2, the virus that causes COVID-19. The Trump administration’s initiative has now spent more than $ 8 billion on experimental vaccines that may or may not be able to process it through the finish line.

“Historical moment: Large-scale trials of potential vaccines against COVID-19 are beginning

Warp speed: Officials reject criticism, saying “We are taking all possible steps” regarding a safe vaccine against COVID-19

Expert panel: The early success of the COVID-19 vaccine fuels optimism, but experts warn that “a lot has to go right”

They are produced “under threat” – before they receive a license. If any of the vaccines are not approved, the accumulated doses will be destroyed.

The companies are working with the US Department of Health and Human Services and the Department of Defense to expand their manufacturing facilities in the United States.

The Sanofi Experimental Vaccine uses DNA and a never-before-released experimental SARS vaccine. Clinical trials of the first and second phase vaccines will begin in September, said Thomas Triumph, Sanofi’s global head of the vaccine wing.

The potential vaccine may start a phase 3 study, the final phase before obtaining a license, by the end of 2020. If this proves to be safe and effective, companies expect to need regulatory approval in the first half of 2021.

This is the fourth deal in which the federal government has pledged to buy doses if companies develop successful coronavirus vaccines.

CLOSE

Dr. Anthony Foci said Tuesday that the development of a coronavirus vaccine was moving at a rapid pace. Foki spoke when President Donald Trump on Tuesday voiced strong support for denying the use of the malaria drug as a treatment, the coronavirus. (July 28)

AP Patriotic

According to the agreement signed in May, the British-Swedish company AstraZeneca will receive $ 1.2 billion for 300 million doses. A $ 1.95 billion deal with US Pfizer for 100 million doses was announced in July. And in July, Maryland Novawax said it would receive $ 1.6 billion from the government to fund the development, testing and 100 million doses of its vaccine candidate.

“The vaccine portfolio being prepared for Operation Warp Speed ​​increases the chances that we will receive at least one safe, effective vaccine by the end of this year,” Health and Human Services Minister Alex Hazard said in a written statement.

The latest deal has the “potential to bring hundreds of millions of safe and effective doses to Americans,” he said.

Sanofi and GSK have said they are ready to make the vaccine available worldwide and are increasing production capacity to produce up to 1 billion doses a year.

A candidate for a DNA-based vaccine is one of two companies he is working on. Another is an RNA message vaccine of the same type being developed by Modern.

For the second, they plan to start testing Phase 1 by the end of 2020 and plan that the vaccine will be ready to begin approval of regulations in the second half of 2021.

Read or share this story: https://www.usatoday.com/story/news/2020/07/31/2-1-billion-sanofi-gsk-deal-100-million-coronavirus-vaccine-doses/5554814002/